Crossmark

Progress in adjuvant systemic therapy for breast cancer

Crossref DOI link: https://doi.org/10.1038/s41571-018-0089-9

Published Online: 2018-09-11

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pondé, Noam F.

Zardavas, Dimitrios

Piccart, Martine
License Information

Text and Data Mining valid from 2018-09-11
More Information

Article History

First Online: 11 September 2018

Competing interests

: N.F.P. has received speaker honoraria from Mundipharma. D.Z. works at the Breast International Group, which has received grants from Genentech, Novartis, Pfizer, Puma Biotechnology, Roche, and Tesaro. M.P. has received consultant honoraria from AstraZeneca, Crescendo Biologics, Debiopharm, Huya, Lilly, MSD, Novartis, Odonate, Periphagen, Pfizer, PharmaMar, and Roche/Genentech and is a board member of Radius. She works at Jules Bordet Institute, which has received research grants from AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche/Genentech, Radius, Servier, and Synthon.